Delving into the Latest Updates on Tocilizumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Atlizumab, MRA-SC, Tocilizumab (Genetical Recombination)

+ [14]

Target

IL-6RA

Action

antagonists

Mechanism

IL-6RA antagonists(Interleukin-6 receptor alpha subunit antagonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesNervous System Diseases+ [6]

Active Indication

Interstitial lung disease due to systemic diseaseStill's Disease, Adult-OnsetTakayasu Arteritis+ [15]

Inactive Indication

Amyotrophic Lateral SclerosisAnemiaAnkylosing Spondylitis+ [16]

Originator Organization

Chugai Pharmaceutical Co., Ltd.

Active Organization

Roche Registration GmbH

Chugai Pharmaceutical Co., Ltd.Hoffmann-La Roche, Inc.

+ [7]

Inactive Organization

Gilead Sciences, Inc.F. Hoffmann-La Roche Ltd.Roche Pharma AG

Drug Highest PhaseApproved

First Approval Date

Japan (11 Apr 2005),

Castleman Disease

RegulationEmergency Use Authorization (United States), Orphan Drug (United States), Breakthrough Therapy (United States), Orphan Drug (Japan)

Login to view timeline

Structure/Sequence

Sequence Code 12264H

Source: *****

Sequence Code 12270L

Source: *****

PALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments. Treatable traits, therapeutic targets identified by phenotypes or endotypes (defined by biological mechanism or by treatment response) through validated biomarkers (measurable characteristic reflecting normal or pathogenic processes, or treatment responses), may include multi-omics, cellular, immune, metabolic, endocrine features, or intelligent algorithms. PALETTE Bayesian adaptive design enables parallel investigations of multiple interventions for sepsis, and quick inclusion of pandemic pathogens. PALETTE's new conceptual model will respond to the challenges of standard approaches, i.e. series of sepsis trials, each investigating one or two interventions, expensive, time consuming, and inappropriate in pandemic context.

Start Date01 Apr 2026

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

NCT03787290

/ SuspendedPhase 2IIT

Examining Immune-Based Mechanisms of Action for Mild-Intensity Whole Body Hyperthermia (WBH) in the Treatment of Major Depressive Disorder

Overall, the objective of this pilot study is to utilize the IL-6 receptor antagonist tocilizumab to prospectively evaluate the role of IL-6 in the antidepressant and immunological effects of whole body hyperthermia (WBH). The study seeks to replicate findings thus far that WBH has an antidepressant effect by administering the intervention at a site not involved in studies to date. Moreover, the current proposal may help the investigators better understand the role of IL-6 in the pathogenesis and treatment of depression which might point to novel immune-based interventions for Major Depressive Disorder (MDD). Finally, the current proposal holds promise for better understanding of a novel treatment for MDD, which is among the leading causes of health-related disability in the world.

Start Date01 Dec 2025

Sponsor / Collaborator

The General Hospital Corp.

[+1]

NCT06818266

/ Not yet recruitingPhase 3IIT

Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Pediatric and Adult Patients with Sickle Cell Disease

The purpose of this study is to determine whether a single infusion of tocilizumab is effective in reducing the time to successful weaning from both supplemental oxygen and any respiratory support, in pediatric and adult patients with sickle cell disease (SCD) during acute chest syndrome (ACS).

Start Date01 Apr 2025

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

100 Clinical Results associated with Tocilizumab

Login to view more data

100 Translational Medicine associated with Tocilizumab

Login to view more data

100 Patents (Medical) associated with Tocilizumab

Login to view more data

8,026

Literatures (Medical) associated with Tocilizumab

31 Dec 2025·ANNALS OF MEDICINE

Characteristics, outcomes and the necessity of continued guideline-directed medical therapy in patients with heart failure with improved ejection fraction

Article

Author: Sun, Junfang ; Lu, Yindan ; Lian, Liyou ; Katsouras, Christos S. ; Yao, Hongxia ; Chen, Qin-Fen ; Zhou, Xiao-Dong ; Li, Mingming ; Lin, Wei-Hong ; Liu, Chenyang ; Feng, Xiaofang ; Peng, Yangdi

BACKGROUND:

Much remains to be learned about patients with heart failure with improved ejection fraction (HFimpEF).

OBJECTIVE:

This study sheds light on the characteristics and clinical outcomes of HFimpEF patients, including the consequences of halting guideline-directed medical therapy (GDMT).

METHODS:

This retrospective study was conducted on patients diagnosed with heart failure with reduced ejection fraction (HFrEF) who underwent a second echocardiogram at least 6 months apart between January 2009 and February 2023. The primary outcomes were major adverse cardiovascular events (MACEs), including all-cause mortality and heart failure hospitalization. The second outcome was recurrent HFrEF.

RESULTS:

Of 4,560 HFrEF patients were included, 3,289 (72.1%) achieved HFimpEF within a median follow-up period of 3.4 years (IQR: 1.8 - 5.9 years). Among these HFimpEF patients, recurrent HFrEF was observed in 941 (28.6%) patients during a median follow-up period of 2.3 years (IQR: 0.8-4.6 years). The proportion of patients who halted GDMT was 70.4%, 53.2%, 59.8% and 63.8% for MRA, beta-blockers, ACEI/ARB/ARNI and SGLT-2 inhibitors. Multivariable Cox analysis revealed ischemic heart disease, chronic kidney disease, coronary heart disease, lower left ventricular ejection fraction, larger left ventricular diastolic dimension and non-use GDMT are associated with recurrent HFrEF. Individuals without GDMT use exhibited lower chances of persistently recovering ejection fraction and high risks of MACEs compared to those who continue use.

CONCLUSIONS:

HFimpEF is a common condition across all clinical follow-ups. Prevalent discontinuation of GDMT medications may contribute significantly to recurrent HFrEF, placing patients at a higher risk for poor prognosis.

01 Jun 2025·International Journal of Pharmaceutics-X

Exploring the potential of antifungal-loaded proniosomes to consolidate corneal permeation in fungal keratitis: A comprehensive investigation from laboratory characterization to microbiological evaluation

Article

Author: Attia, Heba ; Ahmed, Sadek ; Farag, Michael M ; Nemr, Asmaa Ashraf ; Adel, Islam M ; Balkhi, Bander

This work aimed to prepare Terconazole loaded proniosomes (TCZ-PNS) utilizing modified coacervation technique for the management of fungal keratitis. Terconazole (TCZ) is a potent antifungal with poor aqueous solubility posing intricacies in its incorporation in ocular formulations. A 2³ factorial design was adopted to probe independent formulation variables including A: Lecithin: cholesterol ratio, B: Surfactant: cholesterol ratio and C: Span® 80 contribution (% of total SAA). The formulae, generated by the design, were prepared and scrutinized regarding entrapment efficiency (%EE), particle size (PS), polydispersity index (PDI) and zeta potential (ZP). Numerical desirability algorithms selected an optimum TCZ-PNS which boasted plausible %EE (89.51 % ± 0.94 %), nanoscale vesicles consistent with TEM measurements (247.9 ± 0.42 nm), a sufficiently high ZP (-43.42 ± 0.85 mV), and an in-vitro biphasic release profile that remained stable even after Gamma irradiation and short-term storage. The transcorneal ex-vivo permeation of TCZ-PNS was higher than that of TCZ suspension (≈ 2-fold). The formulation was further evaluated for pH, corneal hydration threshold, and histopathological safety, confirming its suitability for ocular application. Confocal laser microscopy revealed substantial corneal uptake (approximately twice as deep as of TCZ suspension). Additionally, microbiological assessments of the optimal TCZ-PNS compared to TCZ suspension demonstrated an inhibition zone nearly 50 % larger, a significantly lower MIC and MFC (64-fold reduction), and enhanced biofilm inhibition activity across most tested concentrations. These findings suggest that TCZ-PNS could be a propitious treatment choice to deeply deliver antifungal therapy for the eradication of deeply rooted and inaccessible fungal keratitis.

01 May 2025·CYTOKINE

Inhibition of inflammation by IL-6 blockade in xenotransplantation

Review

Author: Iwanczyk, Zuzanna ; Maenaka, Akihiro ; Cooper, David K C ; Hara, Hidetaka

The inflammatory cytokine interleukin 6 (IL-6) plays a role in both acute and chronic organ allotransplant rejection. Data suggest that IL-6 inhibition may help prevent or reverse rejection, with large multi-center trials now underway. However, the evidence for the benefit of IL-6 inhibitors in xenotransplantation is limited. IL-6 inhibition has been explored in nonhuman-primate models of xenotransplantation, but no clear consensus exists on its efficacy or the best mode of IL-6 inhibition (anti-IL-6 antibodies, or through IL-6 receptor [IL-6R] blockade). Extra considerations for IL-6 blockade exist in xenotransplantation, as both recipient (human) and xenograft-derived (porcine) IL-6 may play roles. The systemic inflammation seen in xenograft recipients (SIXR) contributes to significant morbidity and mortality for the recipient through coagulation dysfunction and augmentation of the immune response. Anti-IL-6 antibodies (e.g., siltuximab) bind to human IL-6 and prevent IL-6R activation, but do not bind to porcine IL-6, and so have no effect in preventing graft-driven inflammatory processes. In contrast, IL-6R inhibitors (e.g., tocilizumab) inhibit IL-6 activity by blocking binding of human and porcine IL-6 to human IL-6R. Although IL-6R blockade cannot prevent the effect of IL-6 on porcine cells, it probably prevents graft-derived IL-6 from contributing to an inflammatory response in the host. This review outlines the role of IL-6 in xenotransplantation and discusses mechanisms for inhibiting IL-6 to improve recipient survival.

226

News (Medical) associated with Tocilizumab

27 Feb 2025

·pmlive.com

EC approves Celltrion’s RoActemra biosimilar Avtozma for inflammatory diseases

The European Commission (EC) has approved Celltrion’s Avtozma (CT-P47), a biosimilar referencing Roche’s RoActemra (tocilizumab). The drug contains the active ingredient tocilizumab and has been authorised to treat all of RoActemra’s approved indications, including moderate to severely active rheumatoid arthritis, active systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis and giant cell arteritis. A biosimilar, according to the European Medicines Agency, is a biological medicine that is highly similar to one already approved in the EU. This means patients can expect the same safety and effectiveness from the biosimilar as they would from the reference product. Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody designed to inhibit soluble and membrane-bound interleukin‑6 receptors involved in driving inflammatory diseases. The EC’s decision on the drug was supported by a comprehensive data package and totality of evidence demonstrating Avtozma’s biosimilarity to RoActemra, Celltrion said. This included results from a late-stage trial in moderate to severely active rheumatoid arthritis, which demonstrated therapeutic equivalence of Avtozma and RoActemra in treating the chronic inflammatory disease that causes pain, swelling and stiffness in joints. Comparable and sustained efficacy results were observed up to week 52 of the study, and Avtozma was found to be well tolerated with a safety profile comparable to RoActemra. Additionally, no notable safety issues were identified following the single transition from RoActemra to Celltrion’s drug compared with maintenance groups up to week 52. Taehun Ha, senior vice president and head of Europe at Celltrion, said the approval “marks a critical step in [the company’s] mission to provide European healthcare systems with affordable, effective solutions for immunological disorders”. “By leveraging our integrated operations, we strengthen the stability of supply chains and enhance collaboration with European healthcare professionals,” he added. The approval comes just days after the EC approved Biocon Biologics’ Yesintek, an ustekinumab biosimilar referencing Johnson & Johnson’s Stelara, to treat multiple inflammatory diseases. Yesintek has been authorised to treat certain cases of plaque psoriasis, psoriatic arthritis and Crohn’s disease after demonstrating comparable safety and efficacy to the reference product.

Drug ApprovalClinical ResultBiosimilar

24 Feb 2025

·pipelinereview.com

Celltrion Receives EC Approval for Avtozma® (CT-P47), a Biosimilar to RoActemra® (tocilizumab)

INCHEON, South Korea I February 23, 2025 I Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma ® (CT-P47), a biosimilar referencing RoActemra ® (tocilizumab). Avtozma ® has been approved for all indications of its reference product, including moderate to severely active rheumatoid arthritis (RA), active systemic juvenile idiopathic arthritis (sJIA), polyarticular juvenile idiopathic arthritis (pJIA) and giant cell arteritis (GCA). 1 The approval further strengthens Celltrion’s growing immunology portfolio. “Today’s approval of Avtozma ® , a biosimilar to RoActemra ® , marks a critical step in Celltrion’s mission to provide European healthcare systems with affordable, effective solutions for immunological disorders. By leveraging our integrated operations, we strengthen the stability of supply chains and enhance collaboration with European healthcare professionals,” said Taehun Ha, Senior Vice President and Head of Europe at Celltrion. “We are committed to delivering value-driven solutions tailored to the unique needs of the European market.” The EC approval on Avtozma ® was supported by a comprehensive data package and totality of evidence, including the results from a phase III study demonstrating biosimilarity between Avtozma ® and the reference product. The primary endpoint was met in terms of mean change from baseline in Disease Activity Score (DAS) using 28 joints (DAS28)-ESR at Week 12, and the final results supported comparability in secondary efficacy, pharmacokinetics (PK), safety and immunogenicity results between Avtozma ® and RoActemra ® . 2,3 Avtozma ® is Celltrion’s twelfth biosimilar product approved by the EC, following the approval of Remsima ® (intravenous infliximab), Remsima ® SC (subcutaneous infliximab), Yuflyma ® (adalimumab), SteQeyma ® (ustekinumab), Truxima ® (rituximab), Herzuma ® (trastuzumab), Vegzelma ® (bevacizumab), Omlyclo ® (omalizumab), Eydenzelt ® (aflibercept), Stoboclo ® and Osenvelt ® (denosumab). About CT-P47 Phase III Clinical Trial 2,3 This was a Phase III, randomised, active-controlled, double-blind trial to compare the efficacy and safety of Avtozma ® (CT-P47) and RoActemra ® (tocilizumab) in patients with moderate to severely active rheumatoid arthritis (RA). Therapeutic equivalence of CT-P47 and reference tocilizumab in treating RA was demonstrated and supported by comparable and sustained efficacy results up to Week 52. CT-P47 was also well tolerated with a safety profile comparable to reference tocilizumab, and no notable safety issue was identified following the single transition from reference tocilizumab to CT-P47 compared with maintenance groups up to Week 52. About Avtozma ® (CT-P47, biosimilar tocilizumab) Avtozma ® , containing the active ingredient tocilizumab, is a recombinant humanised monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist. Based on data from the global Phase III clinical trial, designed to evaluate the efficacy, pharmacokinetics, safety, and immunogenicity of Avtozma ® compared to the reference product 2,3 , Avtozma ® has been approved for all indications of its reference product, including moderate to severely active rheumatoid arthritis (RA), active systemic juvenile idiopathic arthritis (sJIA), polyarticular juvenile idiopathic arthritis (pJIA) and giant cell arteritis (GCA). 1 Avtozma ® was also approved by the U.S. FDA in January 2025. About Celltrion Celltrion is a leading biopharmaceutical company that specialises in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people’s lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world’s first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, haematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us and stay updated with our latest news and events on our social media – LinkedIn , Instagram , X , and Facebook . SOURCE: Celltrion

Drug ApprovalPhase 3Clinical ResultBiosimilar

24 Feb 2025

·www.pharmaceutical-technology.com

EC authorises Celltrion’s Avtozma for multiple indications

Avtozma is the 12th biosimilar from Celltrion to receive approval from the EC. Credit: © CELLTRION INC. All Rights Reserved. Celltrion has secured marketing authorisation from the European Commission (EC) for Avtozma (CT-P47), a biosimilar to Chugai Pharmaceutical’s RoActemra (tocilizumab). The approval allows Avtozma to be used for the same range of conditions as RoActemra: moderate to severely active rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis, giant cell arteritis and active systemic juvenile idiopathic arthritis. These are significant additions to Celltrion’s immunology offerings. The EC’s decision was underpinned by a data set and evidence totality, which included findings from a Phase III trial. The study confirmed Avtozma’s biosimilarity to its reference product, achieving its primary endpoint with the mean change from baseline in Disease Activity Score (DAS28)-ESR at week 12. It is the 12th biosimilar from the company to receive EC approval. Celltrion Europe head and senior vice-president Taehun Ha stated: “By leveraging our integrated operations, we strengthen the stability of supply chains and enhance collaboration with European healthcare professionals. We are committed to delivering value-driven solutions tailored to the unique needs of the European market.” A recombinant humanised monoclonal antibody, Avtozma, which contains tocilizumab, works as an interleukin 6 receptor antagonist. The CT-P47 Phase III randomised, double-blind, active-controlled trial compared the efficacy and safety of the antibody and the reference in subjects with moderate to severely active RA. Findings demonstrated therapeutic equivalence between CT-P47 and the reference tocilizumab, with comparable and sustained efficacy up to week 52. CT-P47 was tolerated well, with a safety profile similar to that of the reference tocilizumab. No significant safety concerns were noted following a single transition from RoActemra to CT-P47 up to week 52. In August 2024, the EC approved the company’s SteQeyma (CT-P43), a Stelara (ustekinumab) biosimilar for the treatment of chronic inflammatory conditions.

Drug ApprovalPhase 3Clinical ResultImmunotherapyBiosimilar

100 Deals associated with Tocilizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02596	Tocilizumab	L04AC07	DB06273

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Interstitial lung disease due to systemic disease	United States	Genentech, Inc.	04 Mar 2021
Still's Disease, Adult-Onset	Japan	Chugai Pharmaceutical Co., Ltd.	22 May 2019
Takayasu Arteritis	Japan	Chugai Pharmaceutical Co., Ltd.	25 Aug 2017
COVID-19	European Union	Roche Registration GmbH	16 Jan 2009
COVID-19	Iceland	Roche Registration GmbH	16 Jan 2009
COVID-19	Liechtenstein	Roche Registration GmbH	16 Jan 2009
COVID-19	Norway	Roche Registration GmbH	16 Jan 2009
Cytokine Release Syndrome	European Union	Roche Registration GmbH	16 Jan 2009
Cytokine Release Syndrome	Iceland	Roche Registration GmbH	16 Jan 2009
Cytokine Release Syndrome	Liechtenstein	Roche Registration GmbH	16 Jan 2009
Cytokine Release Syndrome	Norway	Roche Registration GmbH	16 Jan 2009
Giant Cell Arteritis	European Union	Roche Registration GmbH	16 Jan 2009
Giant Cell Arteritis	Iceland	Roche Registration GmbH	16 Jan 2009
Giant Cell Arteritis	Liechtenstein	Roche Registration GmbH	16 Jan 2009
Giant Cell Arteritis	Norway	Roche Registration GmbH	16 Jan 2009
Juvenile Idiopathic Arthritis	European Union	Roche Registration GmbH	16 Jan 2009
Juvenile Idiopathic Arthritis	Iceland	Roche Registration GmbH	16 Jan 2009
Juvenile Idiopathic Arthritis	Liechtenstein	Roche Registration GmbH	16 Jan 2009
Juvenile Idiopathic Arthritis	Norway	Roche Registration GmbH	16 Jan 2009
Oligoarticular Arthritis	European Union	Roche Registration GmbH	16 Jan 2009

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypoxic respiratory failure	Phase 3	United States	Genentech, Inc.	20 Apr 2020
Osteoarthritis	Phase 3	France	Hoffmann-La Roche, Inc.	20 Nov 2015
Pain	Phase 3	France	Hoffmann-La Roche, Inc.	20 Nov 2015
Inflammation	Phase 3	Denmark	Hoffmann-La Roche, Inc.	28 May 2014
Inflammation	Phase 3	Finland	Hoffmann-La Roche, Inc.	28 May 2014
Inflammation	Phase 3	Norway	Hoffmann-La Roche, Inc.	28 May 2014
Inflammation	Phase 3	Sweden	Hoffmann-La Roche, Inc.	28 May 2014
Scleroderma, Systemic	Phase 3	United States	Hoffmann-La Roche, Inc.	01 Mar 2012
Scleroderma, Systemic	Phase 3	Canada	Hoffmann-La Roche, Inc.	01 Mar 2012
Scleroderma, Systemic	Phase 3	France	Hoffmann-La Roche, Inc.	01 Mar 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO2024	Not Applicable	Arthritis	-	Tocilizumab 8 mg/kg	cteidupjxq(pkrikydtwa) = fomavazoel ykoesbcpzq (ovpuabbbsb ) View more	-	14 Sep 2024
NCT02165345 (Pubmed \| Rheumatology (Oxford))	Phase 1	Systemic onset juvenile chronic arthritis interleukin-6 \| soluble interleukin-6 receptor \| erythrocyte sedimentation rate ... View more	-	Subcutaneous Tocilizumab	wjxskglujz(ozfuslfjng) = Serious adverse events in the LTE were reported in six patients with pJIA (13.6%; five serious infections) and five patients with sJIA (13.2%; one serious infection) ocilyfwmez (bwdgqzubai )	Positive	01 Sep 2024
NCT02165345 (Pubmed \| Rheumatology (Oxford))	Phase 1		-	Placebo		Positive	01 Sep 2024
EULAR2024 Manual	Not Applicable	Giant Cell Arteritis	196	Tocilizumab	yymrhmtvkm(ikogyoeoam) = wtjpfmufuw mirlulwbop (ymdelafrbd ) View more	Positive	05 Jun 2024
EULAR2024 Manual	Not Applicable	Rheumatoid Arthritis	12,332	TNF inhibitorstocilizumababatacept	rzwuqagyfs(ivtgpynofh) = wbbyvvprbx joxrvrtron (sywzedptic ) View more	Positive	05 Jun 2024
EULAR2024	Not Applicable	Takayasu Arteritis \| Giant Cell Arteritis	-	TOCILIZUMAB (LV-GCA)	zeyatgichq(wyxihfrkfh) = TCZ discontinuation due to severe infections occurred in 4 LV-GCA and 3 TAK patients odzhhnfgiw (axjcijephw ) View more	Positive	05 Jun 2024
EULAR2024	Not Applicable	Takayasu Arteritis \| Giant Cell Arteritis	-	TOCILIZUMAB (TAK)		Positive	05 Jun 2024
EULAR2024	Not Applicable	Rheumatoid Arthritis	-	Intravenous Tocilizumab	akutucmqng(azfpsvgpho) = dykyatbvhx kyzjcopadx (rchffcbxma )	-	05 Jun 2024
EULAR2024	Not Applicable	Rheumatoid Arthritis	137	Rituximab	ikikbkaqmh(ivmzmacckf) = bqhjzbypem hxegpzfnwq (jjmquotaol )	Positive	05 Jun 2024
EULAR2024	Not Applicable	Rheumatoid Arthritis	137	Certolizab	ikikbkaqmh(ivmzmacckf) = wmkskhhnpb hxegpzfnwq (jjmquotaol )	Positive	05 Jun 2024
EULAR2024	Not Applicable	-	-	Tocilizumab biosimilar	zzezywatsq(ulsnfmjome) = xvostoxdcu wmlwvrtcao (tswjmlfhow )	-	05 Jun 2024
EULAR2024	Not Applicable	Afibrinogenemia	-	Tocilizumab	ltpztpijyq(zvckjvclsm) = Hypofibrinogenemia was found in 13 (43.3%) of whom 7 were known to have normal fibrinogen before TCZ. Symptoms including petechiae and ecchymoses were detected in 4, with no bleeding being reported. clqduroxeh (zarianyyvc )	-	05 Jun 2024
EULAR2024	Not Applicable	Autoinflammatory disease	14	Tocilizumab	fnazgbbval(ciytalvzhu) = hapovsqbyk vmwqqybecw (yitnljumuo ) View more	Positive	05 Jun 2024

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Tocilizumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation